Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Characterization of patient mutations in human persulfide dioxygenase (ETHE1) involved in H2S catabolism.
Kabil O, Banerjee R.
J Biol Chem. 2012 Dec 28;287(53):44561-7. doi: 10.1074/jbc.M112.407411. Epub 2012 Nov 9.
Related citations
Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy.
Di Meo I, Auricchio A, Lamperti C, Burlina A, Viscomi C, Zeviani M.
EMBO Mol Med. 2012 Sep;4(9):1008-14. doi: 10.1002/emmm.201201433. Epub 2012 Aug 20.
Ethylmalonic encephalopathy associated with crescentic glomerulonephritis.
Dweikat I, Naser E, Damsah N, Libdeh BA, Bakri I.
Metab Brain Dis. 2012 Dec;27(4):613-6. doi: 10.1007/s11011-012-9313-y. Epub 2012 May 15.
Detoxification of H(2)S by differentiated colonic epithelial cells: implication of the sulfide oxidizing unit and of the cell respiratory capacity.
Mimoun S, Andriamihaja M, Chaumontet C, Atanasiu C, Benamouzig R, Blouin JM, Tomé D, Bouillaud F, Blachier F.
Antioxid Redox Signal. 2012 Jul 1;17(1):1-10. doi: 10.1089/ars.2011.4186. Epub 2012 Apr 17.
Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy.
Giordano C, Viscomi C, Orlandi M, Papoff P, Spalice A, Burlina A, Di Meo I, Tiranti V, Leuzzi V, d'Amati G, Zeviani M.
J Inherit Metab Dis. 2012 May;35(3):451-8. doi: 10.1007/s10545-011-9408-3. Epub 2011 Oct 22.
Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients.
Gehrau R, Maluf D, Archer K, Stravitz R, Suh J, Le N, Mas V.
Mol Med. 2011;17(7-8):824-33. doi: 10.2119/molmed.2011.00072. Epub 2011 Apr 20.
Proteomics reveals that redox regulation is disrupted in patients with ethylmalonic encephalopathy.
Palmfeldt J, Vang S, Stenbroen V, Pavlou E, Baycheva M, Buchal G, Monavari AA, Augoustides-Savvopoulou P, Mandel H, Gregersen N.
J Proteome Res. 2011 May 6;10(5):2389-96. doi: 10.1021/pr101218d. Epub 2011 Mar 28.
Chronic exposure to sulfide causes accelerated degradation of cytochrome c oxidase in ethylmalonic encephalopathy.
Di Meo I, Fagiolari G, Prelle A, Viscomi C, Zeviani M, Tiranti V.
Antioxid Redox Signal. 2011 Jul 15;15(2):353-62. doi: 10.1089/ars.2010.3520. Epub 2011 Feb 25.
Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy.
Viscomi C, Burlina AB, Dweikat I, Savoiardo M, Lamperti C, Hildebrandt T, Tiranti V, Zeviani M.
Nat Med. 2010 Aug;16(8):869-71. doi: 10.1038/nm.2188. Epub 2010 Jul 25.
Ethylmalonic encephalopathy: application of improved biochemical and molecular diagnostic approaches.
Drousiotou A, DiMeo I, Mineri R, Georgiou T, Stylianidou G, Tiranti V.
Clin Genet. 2011 Apr;79(4):385-90. doi: 10.1111/j.1399-0004.2010.01457.x.
Clinical heterogeneity in ethylmalonic encephalopathy.
Pigeon N, Campeau PM, Cyr D, Lemieux B, Clarke JT.
J Child Neurol. 2009 Aug;24(8):991-6. doi: 10.1177/0883073808331359. Epub 2009 Mar 16.
Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy.
Tiranti V, Viscomi C, Hildebrandt T, Di Meo I, Mineri R, Tiveron C, Levitt MD, Prelle A, Fagiolari G, Rimoldi M, Zeviani M.
Nat Med. 2009 Feb;15(2):200-5. doi: 10.1038/nm.1907. Epub 2009 Jan 11. Erratum in: Nat Med. 2009 Feb;15(2):220.
Identification of new mutations in the ETHE1 gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy.
Mineri R, Rimoldi M, Burlina AB, Koskull S, Perletti C, Heese B, von Döbeln U, Mereghetti P, Di Meo I, Invernizzi F, Zeviani M, Uziel G, Tiranti V.
J Med Genet. 2008 Jul;45(7):473-8. doi: 10.1136/jmg.2008.058271.
Ethylmalonic encephalopathy: clinical and biochemical observations.
Zafeiriou DI, Augoustides-Savvopoulou P, Haas D, Smet J, Triantafyllou P, Vargiami E, Tamiolaki M, Gombakis N, van Coster R, Sewell AC, Vianey-Saban C, Gregersen N.
Neuropediatrics. 2007 Apr;38(2):78-82.
Structure of an ETHE1-like protein from Arabidopsis thaliana.
McCoy JG, Bingman CA, Bitto E, Holdorf MM, Makaroff CA, Phillips GN Jr.
Acta Crystallogr D Biol Crystallogr. 2006 Sep;62(Pt 9):964-70. Epub 2006 Aug 19.
Persistent increase of plasma butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and ethylmalonic encephalopathy.
Merinero B, Pérez-Cerdá C, Ruiz Sala P, Ferrer I, García MJ, Martínez Pardo M, Belanger-Quintana A, de la Mota JL, Martin-Hernández E, Vianey-Saban C, Bischoff C, Gregersen N, Ugarte M.
J Inherit Metab Dis. 2006 Oct;29(5):685. Epub 2006 Aug 12.
A case of ethylmalonic encephalopathy with atypical clinical and biochemical presentation.
Di Rocco M, Caruso U, Briem E, Rossi A, Allegri AE, Buzzi D, Tiranti V.
Mol Genet Metab. 2006 Dec;89(4):395-7. Epub 2006 Jul 7.
Ethylmalonic encephalopathy-report of two cases.
Heberle LC, Al Tawari AA, Ramadan DG, Ibrahim JK.
Brain Dev. 2006 Jun;28(5):329-31. Epub 2006 Jan 10.
ETHE1 mutations are specific to ethylmalonic encephalopathy.
Tiranti V, Briem E, Lamantea E, Mineri R, Papaleo E, De Gioia L, Forlani F, Rinaldo P, Dickson P, Abu-Libdeh B, Cindro-Heberle L, Owaidha M, Jack RM, Christensen E, Burlina A, Zeviani M.
J Med Genet. 2006 Apr;43(4):340-6. Epub 2005 Sep 23.
Brain mitochondrial impairment in ethylmalonic encephalopathy.
Grosso S, Balestri P, Mostardini R, Federico A, De Stefano N.
J Neurol. 2004 Jun;251(6):755-6. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on